CPRX Q2 2023 Earnings — Catalyst Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

CPRXCatalyst Pharmaceuticals, Inc.

$3B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$100M+87.5% YoY

Gross Profit

$88M87.9% margin

Operating Income

$47M46.9% margin

Net Income

$38M37.9% margin

EPS (Diluted)

$0.33

QoQ Revenue Growth

+16.7%

Cash Flow

Operating Cash Flow

$31M

Free Cash Flow

$31M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$444M

Total Liabilities

$69M

Stockholders' Equity

$375M

Cash & Equivalents

$179M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$100M	$53M	+87.5%
Gross Profit	$88M	$45M	+92.5%
Operating Income	$47M	$29M	+63.5%
Net Income	$38M	$22M	+74.7%

Revenue Segments

Product Revenue Net

$99M100%

License And Other Revenue

$105,0000%